[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020008746A - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. - Google Patents

7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer.

Info

Publication number
MX2020008746A
MX2020008746A MX2020008746A MX2020008746A MX2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A MX 2020008746 A MX2020008746 A MX 2020008746A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
liver cancer
derivatives
sup
Prior art date
Application number
MX2020008746A
Other languages
Spanish (es)
Inventor
Hongying Yun
Carola Ries
Hong Shen
Sabine Hoves
Thomas Poeschinger
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020008746A publication Critical patent/MX2020008746A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds of formula (I), wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.
MX2020008746A 2018-02-28 2019-02-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer. MX2020008746A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (en) 2018-02-28 2019-02-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Publications (1)

Publication Number Publication Date
MX2020008746A true MX2020008746A (en) 2020-09-28

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008746A MX2020008746A (en) 2018-02-28 2019-02-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer.

Country Status (19)

Country Link
EP (1) EP3758707A1 (en)
JP (1) JP7089596B2 (en)
KR (1) KR20200128414A (en)
CN (1) CN111801100B (en)
AR (1) AR114419A1 (en)
AU (1) AU2019228654A1 (en)
BR (1) BR112020016509A2 (en)
CA (1) CA3091950A1 (en)
CL (1) CL2020002139A1 (en)
CO (1) CO2020010306A2 (en)
IL (1) IL276817A (en)
MA (1) MA52412A (en)
MX (1) MX2020008746A (en)
PE (1) PE20211456A1 (en)
PH (1) PH12020551343A1 (en)
RU (1) RU2020131012A (en)
SG (1) SG11202008291XA (en)
TW (1) TW202003518A (en)
WO (1) WO2019166432A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (en) 2016-08-29 2019-01-30 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
DK3759113T3 (en) 2018-02-28 2024-10-28 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3, 5-dione derivative and similar compounds as inhibitors of orthomyxovirus replication for the treatment of influenza
KR102409595B1 (en) 2020-06-29 2022-06-17 한국과학기술연구원 Novel purinone derivatives as protein kinase CSF-1R inhibitor
CN112420196A (en) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 Prediction method and system for survival rate of acute myocardial infarction patient within 5 years
WO2024013205A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (en) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 Heterocyclic compounds
TWI557117B (en) 2008-12-09 2016-11-11 吉李德科學股份有限公司 Intermediate compounds for preparation of compounds useful as modulators of toll-like receptors
JP5913093B2 (en) * 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
US8507507B2 (en) * 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
ES2691671T3 (en) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US20120039916A1 (en) * 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
EP3294740B1 (en) * 2015-05-08 2019-09-04 H. Hoffnabb-La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
RU2751349C2 (en) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-substituted sulfonimidoylpurinones for the treatment and prevention of viral infection
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Also Published As

Publication number Publication date
KR20200128414A (en) 2020-11-12
AU2019228654A1 (en) 2020-09-03
CL2020002139A1 (en) 2021-01-04
SG11202008291XA (en) 2020-09-29
PH12020551343A1 (en) 2021-06-21
CN111801100B (en) 2023-10-24
IL276817A (en) 2020-10-29
TW202003518A (en) 2020-01-16
CN111801100A (en) 2020-10-20
PE20211456A1 (en) 2021-08-05
JP2021514972A (en) 2021-06-17
RU2020131012A (en) 2022-03-28
AR114419A1 (en) 2020-09-02
EP3758707A1 (en) 2021-01-06
CO2020010306A2 (en) 2020-08-31
BR112020016509A2 (en) 2020-12-15
JP7089596B2 (en) 2022-06-22
MA52412A (en) 2021-06-02
CA3091950A1 (en) 2019-09-06
WO2019166432A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
MX2023010806A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones.
MX2023001876A (en) Rapamycin derivatives.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2016017030A (en) Mnk inhibitors and methods related thereto.
MX2021006902A (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection.
MX2020008746A (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer.
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
MX2020001235A (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs.
MX2021013075A (en) Oxysterols and methods of use thereof.
TN2016000501A1 (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors.
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EP3693369A3 (en) Bromodomain inhibitors
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021005052A (en) Oxysterols and methods of use thereof.
MX2020012827A (en) Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2021012105A (en) Pyrrole compounds.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
MX2021014458A (en) Tricyclic compounds.
MX2019011558A (en) Novel substituted n&#39;-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2